Trials / Completed
CompletedNCT00329927
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated, (Adjuvanted With MF59C.1) Influenza Vaccine, Formulation 2006-2007, When Administered to Elderly Subjects.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- —
Summary
To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 65 years and over
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07 |
Timeline
- Start date
- 2006-06-01
- First posted
- 2006-05-25
- Last updated
- 2006-09-14
Locations
2 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00329927. Inclusion in this directory is not an endorsement.